| 000 | 05539cam a2200457Ia 4500 | ||
|---|---|---|---|
| 999 |
_c6068 _d6068 |
||
| 001 | 6068 | ||
| 003 | ES-VaUE | ||
| 005 | 20200617152725.0 | ||
| 006 | m o d | ||
| 007 | cr un|---aucuu | ||
| 008 | 191019s2020 sz o 000 0 eng d | ||
| 017 | _a1125993770 | ||
| 020 | _a3030254941 | ||
| 020 |
_a9783030254940 ( _q) ( _qelectronic bk.) |
||
| 020 |
_z9783030254933 ( _q) ( _qprint) |
||
| 024 | 8 | _a10.1007/978-3-030-25 | |
| 024 | 1 |
_aAU@ _b000066201557 |
|
| 040 |
_aEBLCP _beng _epn _cEBLCP _dGW5XE _dLQU _dN$T _dOCLCQ |
||
| 050 |
_aRC961.5 _b.N83 2020 |
||
| 245 | 0 | 0 |
_aNuclear medicine in infectious diseases _cAlberto Signore, Andor W.J.M. Glaudemans, editors |
| 260 |
_aCham, Switzerland _bSpringer _c2020 |
||
| 300 | _a1 online resource (279 pages) | ||
| 336 |
_atext _btxt [ _2rdacontent] |
||
| 337 |
_acomputer _bc [ _2rdamedia] |
||
| 338 |
_aonline resource _bcr [ _2rdacarrier] |
||
| 500 | _a4.3 Spect Quantitation and Its Relevance for Imaging Infections | ||
| 505 | 0 | _aIntro; Foreword; Preface; Contents; 1: Infections: The Emergency of the New Millennium; 1.1 Introduction; 1.2 From Optimism to the Harsh Reality: The History of Infectious Diseases in the Past Century; 1.3 What Are Emerging Infectious Diseases (EIDs)?; 1.4 The New Millennium: Infectious Disease Threats; 1.5 The Healthcare-Associated Infections and Their Burden of Antimicrobial Resistance in the New Millennium; 1.6 Conclusions; References; 2: Gamma Camera Imaging of Infectious Diseases; 2.1 Clinically Validated and Commercially Available Radiopharmaceuticals | |
| 505 | 8 | _a2.1.1 111In-8-Hydroxyquinoline and 99mTc-Exametazime2.1.2 Gallium-67 Citrate; 2.1.3 99mTc-Besilesomab; 2.2 Experimental Radiopharmaceuticals; 2.2.1 99mTc-Ciprofloxacin; 2.2.2 99mTc-Ubiquicidin 29-41; 2.3 Future Perspectives and New Trends; References; 3: Radiopharmaceuticals for PET Imaging of Infection; 3.1 Introduction; 3.2 Clinically Validated/Tested and Commercially Available Radiopharmaceuticals; 3.2.1 [18F]FDG; 3.2.1.1 [18F]FDG and Different Microorganisms; 3.2.1.2 FDG Imaging of Some Site-Specific Infections Which Have Been Validated; Osteomyelitis; Spondylodiscitis | |
| 505 | 8 | _aDiabetic FootHip and Knee Prosthesis; Infected Vascular Graft; Infective Endocarditis; Cardiac Implantable Electronic Device Infections; 3.2.2 Labeled White Blood Cells; 3.2.3 [68Ga]Citrate; 3.2.4 Peptides; 3.2.5 Ubiquicidin (UBI) Fragments; 3.3 Experimental Radiopharmaceuticals; 3.3.1 Peptides; 3.3.1.1 Depsipeptide Derivative; 3.3.1.2 K-A9 Peptide; 3.3.2 Antibiotics; 3.3.2.1 Ciprofloxacin; 3.3.2.2 Trimethoprim; 3.3.2.3 Puromycin; 3.3.2.4 Rifampicin; 3.3.2.5 Isoniazid; 3.3.2.6 Pyrazinamide; 3.3.2.7 Fluconazole; 3.3.3 Antibody Labeling | |
| 505 | 8 | _a3.3.3.1 Antibodies Against Gram-Negative Bacteria3.3.3.2 Antibodies Against Gram-Positive Bacteria; 3.3.3.3 Antibody Against Simian Immunodeficiency Virus Envelope Protein; 3.3.3.4 Aspergillus Fumigatus-Specific Monoclonal Antibody JF5; 3.3.4 Imaging Targeted Molecules or Metabolism Specific to Microorganisms; 3.3.4.1 Siderophores; 3.3.4.2 Carbohydrate Metabolism; 3.3.5 Other Metabolites; 3.3.5.1 Fialuridine (FIAU); 3.3.5.2 Para-Aminobenzoic acid (PABA); 3.3.5.3 d-Methionine; 3.3.5.4 Prothrombin; 3.3.5.5 Transferrin | |
| 505 | 8 | _a3.3.6 Nonspecific Tracers Used in Infection to Discriminate Infection from Malignancy3.3.6.1 [18F]fluorothymidine ([18F]FLT); 3.4 Conclusion and Future Perspective; References; 4: Hybrid SPECT/CT and PET/CT Imaging in Infectious Diseases; 4.1 Introduction; 4.2 SPECT/CT Characteristics; 4.2.1 Basic Concepts; 4.2.1.1 Planar Imaging; 4.2.1.2 SPECT and SPECT/CT; 4.2.2 Improved Anatomical Location; 4.2.3 Motion Correction and Iterative Reconstructions; 4.2.4 Attenuation and Scatter Correction; 4.2.5 Disadvantages; 4.2.6 Partial Volume Effects | |
| 520 | _aThis book is designed as a reference manual that is exceptional in systematically discussing every aspect of nuclear medicine imaging of infections, with careful explanation of the most up-to-date concepts and recent guidelines on diagnostic flowcharts as shared between the EANM, ESR, ESNR, ESCMID, ESC, EACVI, ECCO, ESGAR and EBJIS. It is truly comprehensive, describing all methods, all acquisition parameters, and all interpretation criteria in all infectious diseases. The early chapters discuss currently available radiopharmaceuticals and nuclear medicine imaging technologies, including the hybrid modalities SPECT/CT, PET/CT, and PET/MRI. The remainder of the book is devoted to the nuclear medicine imaging of infections at different body sites as well as fever of unknown origin, fungal infections, and tuberculosis and AIDS-associated infections. Infections represent a real emergency globally, and early diagnosis and treatment follow-up will continue to pose huge challenges. In this context, Nuclear Medicine in Infectious Diseases will be a superb asset for nuclear medicine and infectious disease specialists and other clinicians everywhere | ||
| 650 | 0 |
_aCommunicable diseases- _xImaging |
|
| 655 | 4 | _aElectronic books | |
| 700 | 1 |
_aSignore, A. ( _qAlberto) _d1959- |
|
| 700 | 1 |
_aGlaudemans, Andor W. J. M. ( _qAndor Waltherus Johannes Maria _d1976- |
|
| 776 | 0 | 8 |
_iPrint version _aSignore, Alberto _tNuclear Medicine in Infectious Diseases _dCham : Springer 2019 _z9783030254933 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/book/10.1007/978-3-030-25494-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia) |
| 942 |
_2lcc _cLE |
||
| 998 | _db | ||